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Glucose transport is key for cellular metabolism as well as physiological function and is maintained via 
passive facilitated and active sodium-glucose linked transport routes. Here, we present for the first time 
Fourier-transform infrared spectroscopy as a novel approach for quantification of apical-to-basolateral 
glucose transport of in vitro cell barrier models using liver, lung, intestinal and placental cancer cell lines. 
Results of our comparative study revealed that distinct differences could be observed upon subjection to 
transport inhibitors. 
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The human body relies on glucose as its main source of energy to maintain physiologic tissue, organ and cell function1. Dietary 
uptake of glucose occurs in the digestive tract through intestinal absorption, from where glucose molecules are further distributed 
via the circulatory system2. The distribution process involves epithelial barriers regulating glucose transport either by paracellular 
or transcellular carrier-mediated transport1, 3. This carrier-mediated transport of glucose relies on two distinct types of glucose 
transporter families, whose members can vary in function, tissue distribution and glucose affinity4. Within tissue types that are 
crucial for absorption and reabsorption of glucose (e.g. gut or kidney), active transport against a glucose gradient is achieved by 
sodium-glucose linked transporters (SGLT)5. This type of transporter mediates glucose transport into the epithelium by co-
transporting sodium ions from the extracellular space along an established sodium gradient. In contrast, diffusion of glucose 
along an electrochemical gradient of the monosaccharide is facilitated by the glucose uniporter family (GLUT)6, which is 
ubiquitously distributed among various tissue types such as lung7 or placenta8. For instance, the most common subtype of the 
GLUT transporters, GLUT1, is present in the blood-brain-barrier9 as well as in various blood-tissue barriers10 including the 
human placenta11. Because glucose transporters are of the utmost importance for glucose homeostasis within the human body, 
mutations thereof can result in several severe diseases. For example, mutations in GLUT2 and GLUT4 genes are linked to 
diabetes type II12 whereas malfunction of the GLUT1 transporter leads to GLUT1-deficiency syndrome causing neural disorders, 
seizures and ataxia13. Mutations in SGLT1 on the other hand cause fatal malabsorption in the intestines5. The prevalence of both 
GLUTs and SGLTs throughout the human body render them an important target for investigation of cell-based in vitro models. 
By employing cells of the respective organ, many studies try to recapitulate barrier function and transport in vitro, generating 
suitable and more physiologically relevant organ models as well as drug testing platforms14. Many barrier models make use of 
cancer cell lines, which provide several advantages such as cost effectiveness, ease of continuous cultivation as well as 
reproducibility15, 16. So far, various methods for detection and quantification of glucose have been established including 
chromatography, mass spectrometry and electrophoresis, as well as enzymatic, enzyme-free and fluorescence-based assays17-19. 
While enzymatic detection systems are specific to glucose and enable relatively high throughput due to a microtiter plate format, 
non-enzymatic instrumentation such as chromatography and mass spectrometry offer broad applicability due to their ability to 
simultaneously analyse other analytes20. A more detailed overview over the state-of-the-art and progress of glucose monitoring 
and detailed working principles has been reviewed recently19.   Routinely, whole blood glucose is detected in the field using 
electrochemical methods such as amperometry, which, to date, constitutes the most successful and prominent glucose biosensor 
for point-of-care diagnostics21. Fourier-transform infrared (FTIR) spectroscopy is another fast and label-free alternative 
biosensing approach and has been applied for the detection of glucose from human blood and serum samples among many other 
samples such as cell culture processes, enzymes and proteins 22-27. Recently, FTIR spectroscopy has been under investigation as 
suitable technique for the clinical detection of glucose in vivo, during ex vivo blood dialysis, for monitoring of pro- and eukaryotic 
bioprocesses and fermentations23, 24, 28-31. However, up to now no study has applied Fourier-transform infrared spectroscopy as a 
simple and rapid strategy for the assessment of glucose transport levels of in vitro cell barrier models. Therefore, we introduce 
FTIR spectroscopy for glucose quantification from complex artificial matrices such as cell culture supernatants derived from in 
vitro barrier models grown in Transwell inserts. After initial characterization of the non-invasive method to detect glucose in 
standard cell culture medium as well as phosphate buffered saline, FTIR spectroscopy was used to compare the overall glucose 
transport across several well-established cancer-derived in vitro models including pulmonary, placental, hepatic and intestinal 
epithelial barriers (for comparison of in vitro and in vivo glucose transporters see Figure 1). The barrier models were first 
characterized for proper barrier integrity over a time-course of eight days using transepithelial electrical resistance (TEER) 
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measurements16 as well as metabolic and fluorescent as well as Live/Dead assays. As a proof-of-principle, we apply Fourier-
transform infrared spectroscopy in a comparative study of glucose transport and inhibition of pulmonary, placental, and hepatic 




2.1 Cell Culture  
Placental Bewo cells (kindly provided by Dr. Berthold Huppertz, Medical University of Graz, Austria) were cultivated in 
Dulbecco’s modified Eagle medium (DMEM with L-glutamine and high glucose; Gibco, 11965-084). Intestinal models Caco-2 
and HT-29 cells were maintained in DMEM and additionally 1% non-essential amino acids (NEAA; Gibco, Cat. nr. 11140-035). 
Hep G2 liver cells were cultured in modified Eagle's medium (MEM) (Sigma Aldrich, M4526). The alveolar cell line A549 cells 
were cultivated in RPMI 1640 medium (Sigma Aldrich, D5796). All media were supplemented with 10% FBS and 1% antibiotic 
mix. All cells were cultivated in a humidified atmosphere at 37°C and 5% CO2. 
 
2.2 Preparation of Trans-well Transport Models 
Cells were seeded onto porous polyester trans-well membranes for barrier integrity and glucose transport studies with a growth 
area of 1.2 cm², a pore size of 3.0 µm and placed in 12-well tissue culture plates (Costar, Greiner BioOne). All cells were seeded 
with a total seeding density of 1 x 105 cells/cm² on the apical side of the permeable membrane inserts on day 0. The apical 
chamber was filled with 0.5 ml and the basal compartment with 1.5 ml of the appropriate cell culture medium for each cell type. 
For the no-cell controls, the respective amount of cell culture medium was filled in the apical and the basal chambers. The 
medium was refreshed every second day (on day 1, 3, 5 and 7 post seeding). 
 
2.3 Trans-epithelial electric resistance (TEER) measurements 
All TEER measurements were performed with an EVOM2 voltmeter equipped with a STX2 electrode (World Precision 
Instruments Ltd). TEER was measured and averaged at three different well positions. Electrodes were immersed in cell culture 
media before measurements for about 30 minutes, while the device was allowed to warm up. TEER analysis was performed at 
room temperature after refreshing the medium. The resistance values were expressed as unit area resistance (Ω*cm²) and 
therefore data was baseline subtracted from acellular control and multiplied by trans-well area. 
 
2.4 Cell viability evaluation 
Cell viability was evaluated using a PrestoBlue™ (Thermo Fisher, 1824890). Cells were seeded in trans-wells at an initial seeding 
density of 1 * 105 cells/cm² on 48-well tissue culture plates. Culture medium was exchanged every other day. On day 1, 3, 5 and 
7, PrestoBlue assay was performed according to the manufacturer’s protocol using 200 µl of 10% detection mix. After an 
incubation time of 60 minutes at 37°C, 100 μl were transferred into 96-well plates and analyzed using an EnSpire 2300 plate 
reader (Ex. 560 nm/Em. 590 nm; Perkin Elmer). The fluorescence values were averaged, baseline subtracted and expressed as 
% viability normalized to day 1. For a visual inspection of viability, a live/dead staining based on Calcein AM and Ethidium 
Homodimer-1 (EthD-1) (Thermo Fisher, 1906259) was performed in parallel in collagen-coated 48-well plates. Medium was 
replaced with a dual staining solution and incubated for 30 minutes in the dark at 37 °C. Images were taken with an IX83 
microscope (Olympus, Austria) using GFP (Ex. 495 nm/ Em. 515 nm) and rhodamine (Ex. 495 nm/ Em. 635 nm ) filter sets.  
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2.5 Preparation of glucose inhibitors 
Cytochalasin B from drechslera dematioidea (Sigma Aldrich, C6762) was dissolved in dimethyl sulfoxide (DMSO) at a final 
working concentration of 20 µM in the respective full culture medium. Phloretin (Sigma Aldrich, P7912) was dissolved in 99% 
ethanol and then further diluted to 30 µM with the respective cell culture medium. 
 
2.6 Evaluation of glucose transport 
Evaluation of the glucose transport was carried out on day 7 post seeding. The apical chamber was filled with 0.7 ml of high 
glucose DMEM and 1.5 ml of DMEM without glucose (Gibco, 11966-02), referred to as DMEMNO GLUCOSE, was sampled into 
the basal chamber of each transwell. A 50 µl sample of the apical and basal compartment was taken at 0, 60, 105, and 150 minutes 
post exposure. Results were dilution corrected for the removal of 50 µl for each measurement time point. Acellular control 
experiments were performed with the respective amount of DMEMHIGH GLUCOSE and DMEMNO GLUCOSE to monitor maximal 
possible transport. The basal glucose transport rate was calculated with the formula given in Equation S1. It describes the relation 
of differences in basal glucose concentrations, cb, between two neighboring time points to the according time difference. 
 





for 0 < n < 4;  t(n) =  {0 , 1, 1.75, 2.5} h  
 
For inhibition experiments, cell barriers were treated with the inhibitory substances on day 7 post seeding and incubated for 24 
hours in the dark at 37°C. The transport experiments were conducted on day 8 post seeding. Again, the apical chamber was filled 
with 0.5 ml DMEMHIGH GLUCOSE and the basal chamber with 1.5 ml DMEMNO GLUCOSE. Samples of apical and basal compartments 
were taken after 2 hour for cells treated with Cytochalasin B or Phloretin. Glucose transport inhibition was expressed as 
percentage of the untreated cells (controls). 
 
2.7. Quantification of glucose using FTIR spectroscopy 
Fourier-transform infrared spectroscopy of glucose was performed using a platinum ATR sampling unit on an InfraRed Tensor 
37 (Bruker). A 30 µl medium sample was pipetted onto the diamond ATR crystal, which was cleaned with ethanol before each 
measurement. For the reference series, the absorbance spectrum was analysed at the wavelengths of the fundamental vibrations 
of glucose at 1153 cm-1, 1108 cm-1, 1080.5 cm-1, 1035.7 cm-1 and 994.3 cm-1 of the mid infra-red (MIR) region. Four different 
dilution series were prepared for the reference series to analyse the impact of different solvents in the absorbance spectrum. The 
reference sample, DMEMHIGH GLUCOSE solution was diluted down to 0.05 mg/ml with either DMEMNO GLUCOSE, Dulbecco’s 
Phosphate Buffered Saline (PBS) without calcium chloride (CaCl2) and magnesium chloride (MgCl2) PBS (Sigma Aldrich, 
D8537), with CaCl2 and MgCl2 (PBS+; Sigma Aldrich, D8662) or distilled water. Data analysis was performed with OPUS 7.5® 
software. The measurements were recorded with an average of 200 scans at 2 cm-1 resolution, which resulted in a spectra 
acquisition time of 170. seconds. The recorded measurement region covered the mid infrared region from 4000 – 900 cm-1. The 
absorbance spectra were smoothed with 9 smoothing points and integrated. For quantitative evaluation, the height of the 
 5 
absorption band was analyzed. For glucose transport and inhibition studies the band height was analyzed at the wavenumber of 
1035.7 cm-1, if not stated otherwise. 
 
The sensitivity, or slope, k of linear regression was used for the calculation of the limit of quantification (LOQ) and limit of 
detection (LOD). The applied formulas are given in Equation S3-4: 
 
Equation 2:  





Equation 3:  




The root mean square (RMS) noise of the instrument was measured twice from 1200 to 990 cm-1 (with the same number of 
scans) and averaged and the slope of the calibration line was determined for each absorbance band.  
 
2.8. Colorimetric glucose assay 
For the colorimetric approach, the same range of glucose concentrations as for infrared spectroscopy was measured. The standard 
solution of the kit was prepared as per instructions given in the glucose assay kit (Abcam, ab65333). The measurement of 
standards, controls and samples were assayed in duplicate. The highest glucose concentration detectable by the kit is 200 µM 
(=36 *10-3 mg/ml). For the reference series, first D-(+)-Glucose (Sigma Aldrich, Cat. nr. G5400) was dissolved in distilled water, 
to create sugar solutions with concentrations from 25 mM to 560 µM. Secondly, the whole reference series was diluted in a ratio 
of 1:130 to fall below the maximum of 200 µM glucose in the standard series. Standard and samples (reference series) were 
pipetted into a 96-well tissue culture plate. For each measurement 50 µl of reaction mix was added into the standard and sample 
wells. Additionally, 50 µl of background reaction mix was into background control wells. The plate was incubated for 30 minutes 
in the dark at 37°C and then analysed with the EnSpire 2300 plate reader (Ex. 535 nm/Em. 587 nm; Perkin Elmer). 
 
2.9. Fluorescence imaging 
For visualization of nuclei and cytoskeleton 6 µM FITC-conjugated phalloidin solution (Invitrogen) was added for 1 h at room 
temperature followed by the addition of 0.4 µg/ml DAPI (Sigma Aldrich) in DPBS for 5 min.  Samples were washed three times 
with DPBS after each step and embedded in Vectashield® mounting medium (Thermo Fisher) prior to analysis.  All images were 
recorded with in IX83 live-cell microscope (Olympus, Austria) equipped with a Hamamatsu ORCA flash camera. 
 
2.10. Sodium-fluorescein leakage assay 
For evaluation of barrier integrity with sodium fluorescein leakage assay, first, the basal chamber of the transwell inserts was 
filled up with 1.5 ml of cell culture medium on day 0. Next, 1*105 cells cm-2 in 500 µl culture medium were seeded onto the 3 
μm porous polyester membrane of the apical chamber. For acellular controls, only the respective cell culture medium was pipetted 
onto the blank membrane filters. At day 3 and 7 post seeding, medium from the apical chamber was aspirated and replaced with 
500 µl of 100 μM sodium fluorescein solution. At each time point, 50 μl samples from the basal chamber were pipetted into a 




3. Results and discussion 
3.1 Characterization of ATR-FTIR spectroscopy for Transwell-based glucose transport studies 
Even though FTIR spectroscopy has been extensively used for quantification of glucose in blood as well as in serum, 
to date no study has applied this non-invasive and fast label-free method for detection of glucose transport of in vitro cell culture 
models. Therefore, prior to any cell-based experiment, FTIR spectroscopy was characterized to identify the ideal spectral range 
and sensitivity for detection of glucose concentrations from complex cell culture media. Glucose was added in different diluents 
including water, phosphate buffer as well as culture medium. Figure 2A depicts the spectrum of the typical adsorption bands of 
glucose in DMEM culture medium with local maxima at 1153.5 cm-1, 1108 cm-1, 1080.5 cm-1, 1035.7 cm-1 and 994.3 cm-1, 
corresponding well with literature32. The absorbance values at the band maximum of 1035.7 cm-1 show the highest trend in 
absorption due to strong vibrational modes in the C-O and C-C structure of glucose. After this initial assessment, glucose 
detection via FTIR spectroscopy was benchmarked against state-of-the-art colorimetric assays based on glucose oxidase. For the 
colorimetric detection of glucose, a reference series in the range of 4.5 - 0.1 mg/ml glucose was prepared and further diluted 
1:130 to be compatible with the maximum detectable limit of the colorimetric assay. As shown in Figure 2BC, both the 
absorbance data derived from FTIR spectroscopy of any local maxima and the fluorescence intensities of the colorimetric 
detection strategy were in good agreement and showed a linear relationship for increasing concentrations of glucose in the range 
of 0.1 to 4.5 mg/ml. In comparison to the colorimetric detection which resulted in a limit of detection for glucose at approx. 
0.018 mg/ml, FTIR spectroscopy at the most sensitive wavenumber 1035 cm-1 revealed a limit of detection of 0.169 mg/ml. In 
order to investigate the influence of media composition on possible artifacts in the spectrum range of glucose, different dilution 
series of DMEM containing 4.5 mg/ml glucose with either glucose-free medium, sterile distilled water or phosphate buffer were 
investigated. Graphical analysis in Figure 2D revealed no noticeable difference of sensitivity for absorbance data recorded at 
1035.7 cm-1 with LODs for glucose of 0.168 mg/ml, 0.172 mg/ml, 0.170 mg/ml and 0.164 mg/ml for DMEM culture medium, 
deionized water as well as phosphate buffer, respectively. A negligible positive offset for both PBS in the presence and absence 
of CaCl2 and MgCl2 ions (PBS+/PBS-) can be attributed to phosphate interferences at the wavenumber of 1035.7 cm-1. Even 
though not as sensitive as colorimetric assays, glucose concentrations present in cell culture supernatants can easily be detected 
using FTIR spectroscopy without the need for any further laborious dilution or sample preparation steps. 
 
3.2 Characterization of the Transwell barrier models based on cancer cell lines 
 
Integrity of the epithelial barrier is the most important feature for the physiological function of any epithelial transport model. 
Therefore, viability as well as barrier integrity was investigated to ensure proper barrier quality prior to glucose transport 
experiments. In order to evaluate the integrity and coverage of the cell barriers and rule out holes and barrier ruptures, as quality 
control TEER analysis was performed over a period of 8 days for pulmonary, placental, hepatic and intestinal in vitro cell models 
seeded at an initial seeding density of 1*105 cells/cm² in a trans-well set-up. Figure 3A shows that over the course of several 
days, TEER values for all barrier types increased gradually with a unit area resistance on day 7 post seeding peaking at 125.20 
± 5.7 Ωcm² for pulmonary A549 cells, 119.5 ± 11.6 Ωcm² for placental Bewo cells, 80 ± 7.1 Ωcm² for hepatic Hep G2, 134.6 ± 
7.6 Ωcm² for intestinal Caco-2 cells, 101.3 ± 13.2 Ωcm² for intestinal HT29 cells and 171.7 ± 7.2 Ωcm² for the co-culture of 
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Caco-2 with HT29 cells. Overall, the co-culture of Caco-2 with HT29 cells resulted in the highest increase in TEER, whereas 
the Hep G2 cell barrier showed the lowest overall TEER value development at day 7 post-seeding. These results indicate that 
the co-culture of Caco-2 with HT29 cells form a tighter cell barrier in terms of barrier integrity than the individual intestinal 
barrier models, as well as pulmonary, placental or hepatic barrier cell models. Although Caco-2 and HT29 are both colon 
carcinoma cells, they show distinct differences in their TEER development. Caco-2 cells display characteristics of colonocyte 
and enterocyte phenotypes and are known for high TEER values,33 whereas HT29 cells display goblet cell properties and produce 
lower TEER values, which is more physiological when taking in vivo situation into account34. Overall, all barrier cell models 
were considered leakage-free due to gradual increase of resistance over time. 
In addition, viability as well as metabolic activity of the barrier models was determined to rule out influences of cell death or 
loss of barrier integrity for transport studies of glucose from day 7 to day 8 post-seeding. Therefore, a fluorescent live/dead assay 
(Calcein AM/ethidium bromide) and a metabolic PrestoBlue™ assay were performed at day 1, 3, 5, 7 and 8 post-seeding (see 
Figure S1-S2). Even though a few necrotic cells were found floating above tight and healthy cell barriers based on microscopy 
of the Calcein AM and ethidium bromide dye exclusion assay (red fluorescent cells in Figure S1), no signs of barrier impairment 
due to cell layer disruption were observable for any cell type. To further analyse barrier health, PrestoBlue™ assay was performed 
to give a more quantitative reflection of barrier health based on increase of cell metabolism as a function of cell growth and 
viable cells over time. The highest metabolic activity was observed for Caco-2 barriers, followed by Bewo and HT29 barriers at 
day 7 post-seeding and lowest metabolic activity was observed for A549 and HepG2. Overall, all cell lines gradually increased 
metabolic activity over time indicating good barrier viability ranging from 1.5 to 2.5-fold of day 1 indicating gradual and steady 
cell growth of viable barrier cells. It must be noted that loss in cell viability comes a long with decrease of cell metabolism thus 
significant drop in signal, which is not the case for the presented barrier models. Therefore, the few ethidium positive cells can 
be considered negligible with respect to barrier health status. When investigating barrier integrity and morphology in more detail 
using fluorescence staining, confluent cell barriers were already achieved for all cell types as early as day 3 and gradually 
improving to day 7-8, being in line with TEER analysis (see Figure 3A for confluent barrier models). Differences between 
individual cancer-derived cell barrier models cultivated under the same cultivation conditions and initial seeding densities were 
more pronounced at day 7 to 8 when inspecting layer thickness. The results shown in Figure S3BC indicate that thicker barriers 
were observable for intestinal co-cultures between 37.7 ± 23.1 µm height, whereas placental and hepatic cells showed a height 
around 25 and 23 µm, respectively. In contrast, lung A549 showed average height of 3.75 ± 0.82 µm and both intestinal 
monoculture barriers formed cell layers with a height around 6 µm for Caco-2 and 11 µm height for HT29 cells. When comparing 
additional sodium fluorescein leakage assay with previous TEER measurements (see Figure S3D), results revealed steady 
increase in molecular barrier tightness from day 3 to day 7 post-seeding towards cell-impermeable fluorescein which 
corresponded well with increase of resistance values. When combining all these characterizations, Transwell barriers with these 
properties were considered tight and healthy and were as a consequence used for glucose transport studies.  
3.3 ATR-FTIR Analysis of glucose transport and transport inhibition using cytochalasin B and phloretin 
 
Next, FTIR spectroscopy was applied in a comparative study to investigate differences in glucose transport through 
placental, pulmonary, hepatic and intestinal barriers. Therefore, glucose concentrations during the apical-to-basal transport of 
the trans-well experiment were analyzed over a time course of 150 minutes for each cell barrier model and compared to maximum 
transport values for acellular controls. Figure 3B displays the time course of glucose concentrations in basolateral trans-well 
compartments (for more details on the glucose concentrations of each individual barrier model and acellular control samples see 
Figure S4). During the first hour glucose was rapidly taken up by the barrier cells with gradually declining velocity over time. 
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This asymmetric behavior is common for glucose transport in transwell insert systems35. All cell barrier models showed gradually 
increasing values for transported glucose over time with 8.96 ± 1.64 mmol/l/cm2 for Caco-2, 7.71 ± 1.45 mmol/l/cm2 for the co-
culture of Caco-2 and HT29, 7.43 ± 0.43 mmol/l/cm2 for Bewo, A549 with 7.33 ± 1.25 mmol/l/cm2, HT29 with 7.28 ± 1.27 
mmol/l/cm2 followed by Hep G2 cells with 6.19 ± 0.64 mmol/l/cm2 in contrast to the acellular control that peaked at 11.25 ± 1.3 
mmol/l/cm2 after 150 minutes. When calculating transport rates, cighest cellular glucose uptake rates were found for Caco-2 with 
122.1 ± 10.4 µmol/l/min/cm2, Caco-2/HT29 coculture with 102.1 ± 8.7 µmol/l/min/cm2 followed by Bewo with 98.9 ± 12.9 
mol/l/min/cm2, HT19 with 90.8 ± 15.3 µmol/l/min/cm2, HepG2 with 80.9 ± 9.8 µmol/l/min/cm2 and A549 with 62.9 ± 4.5 
µmol/l/min/cm2. Overall, the intestinal barriers Caco-2 and co-culture of Caco-2 with HT29 display the fastest glucose uptake 
thus transfer rates. Surprisingly, the intestinal HT29 monocultures showed slightly slower transfer rates than Caco-2 
monocultures as well as the intestinal co-culture. Overall, these results are not surprising, since the primary tasks of intestines is 
to facilitate the transfer of glucose from the intestinal lumen to the blood36. Also, placental barriers exhibited high transfer rates 
and overshadow the rates of the lung and the hepatic barriers. Again, this aligns with the physiological tissue function of the 
human placenta as fetal development is sustained throughout gestation by high glucose transport rates 8. When discussing these 
values in the light of barrier thickness and TEER, for receptor-mediated glucose transport across transwell in vitro barriers, no 
correlation between layer thickness and transport rates were found indicating that due to its importance for cell and tissue 
homeostasis glucose can even pass multi-layered barriers of the intestine, liver and placenta in a fast and efficient manner. 
In a final set of experiments, FTIR spectroscopy was utilized to investigate the impact of Cytochalasin B (GLUT 
inhibitor) and Phloretin (GLUT/SGLT inhibitor) on reduction of glucose transport for the placental, pulmonary, hepatic and 
intestinal in vitro cell barriers. The individual inhibitors were added at day 7 post seeding and incubated for 24 hours. As shown 
in Figure 4, exposing in vitro cell barriers to 20 µM cytochalasin B resulted in glucose transport reduction of 52.64 ± 10.87% 
for placental barriers, 42.11 ± 13.08% for Hep G2 and 34.66 ± 12.73% for A549 suggesting the strong influence of GLUT-1 and 
GLUT-3 on glucose transport through placental, pulmonary and hepatic barriers.4, 12, 37, 38 Lowest inhibition of GLUT-dependent 
glucose transport was observed for the barriers of Caco-2, Caco-2 / HT29 (co-culture) and HT29 with an overall reduction of 
18.67 ± 7.88%, 12.14 ± 5.53% and 15.59 ± 7.32%, respectively. Glucose transport inhibition with 30 µM phloretin (PT) as 
shown in Figure 3B indicates inhibition of SGLT-1 and most GLUTs expressed in cancer cells lines with the exception of GLUT-
5 (fructose), GLUT-9 (transporter for urate) and GLUT-12.12, 39 Overall, decreased glucose transport to the basolateral transwell 
compartment of 20.18 ± 4.36% for A549, 38.24 ± 12.16% for Bewo and 36.27 ± 9.43% for Hep G2 was observed in comparison 
to transport inhibition via cytochalasin B. In contrast, higher inhibitory effect for the intestinal barriers including Caco-2 with 
45.39 ± 16.24%, HT29 with 24.53 ± 12.10% and co-culture Caco-2 / HT29 with 27.09 ± 7.94% were observed. These results 
indicate a substantial influence of SGLT-1 and GLUT2 transporters on glucose transport in intestinal barrier models40-42. 
4. Conclusions 
To conclude, we demonstrated how ATR-FTIR spectroscopy can be applied as a fast, label-free and comparably cheap method 
for the analysis of receptor-mediated glucose transport across human in vitro cell barriers in transwell assays. In contrast to other 
routinely used detection methods such as colorimetric or other enzyme-based assays, no sample preparation, dilution or 
sophisticated data analysis is necessary to determine conclusive results on glucose level in both apical and basal trans-well 
compartments. Furthermore, in a comparative study we have demonstrated how ATR-FTIR spectroscopy can be used for the 
investigation and characterization of glucose transport and drug-mediated inhibitory effects thereof across a variety of cell-based 
in vitro barrier models, highlighting the broad applicability of the presented analytical approach. 
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Figure 1: (A) Overview of glucose transporters found in human tissue compared to in vitro cell lines including pulmonary A549, 




Figure 2. (A) Glucose absorbance spectrum of the FTIR spectroscopy. The smoothed and integrated spectra is shown in the range 
of 1180 cm-1 to 960 cm-1 for different glucose concentrations in DMEM solutions (B) Comparison of absorbance data from 
FTIR spectroscopy for the wavenumbers 1153.5 cm-1, 1108 cm-1, 1080.5 cm-1, 1035.7 cm-1 and 994.3 cm-1 and (C) 
fluorescence intensity of the enzymatic glucose assay are plotted against the corresponding glucose concentrations. Linear 
regression line is included. (B,C). Absorbance data of FTIR spectroscopy is plotted against corresponding glucose concentrations 
at the wavenumber 1035.7 cm-1. DMEMHIGH GLUCOSE was diluted with either DMEMNO GLUCOSE, distilled water, 
PBS+ or PBS-. Linear regression line for each dilution series is included. (D) Impact of matrix on glucose quantification glucose 









Figure 3 (A) Barrier integrity based on the trans-epithelial electrical resistance of lung A549, placenta Bewo, liver HepG2, as 
well as intestinal Caco-2 and HT29 mono- and co-cultures (co-culture ratio of 90 %Caco-2 + 10% HT29). TEER was measured 
at day 1, 3, 5 and 7 post seeding after fresh medium exchange at room temperature and is expressed as unit area resistance in 
Ωcm² for n=3 with three positions analysed per transwell insert. (B) Basolateral glucose concentrations over a time course of 
150 min for all barrier models and acellular control trans-wells at day 7 post seeding. Data is expressed as mean values ± standard 





Figure 4 Inhibitory effect of 20 µM Cytochalasin B and 30 µM Phloretin on glucose transport across pulmonary A549, placental 
BeWo, hepatic Hep G2, as well as intestinal Caco-2 and HT29 mono- and co-cultures at day 8 post-seeding.  Inhibited glucose 
transport receptors are summarized under the graph for Cytochalasin B and Phloretin. Data is expressed as % of untreated control 
for n=3.  
 
 
 
 
 
